The team at Simont Braun exhibits expertise across a variety of areas, including disputes concerning the corporate branding of generic medicines, and trade mark cases. Practice co-head Eric De Gryse is particularly knowledgeable in international patent cases concerning the market entry of biosimilars and medical devices, while co-head Rafaël Jafferali handles a broad range of class actions and arbitrations before the Belgian Supreme Court. Axel Maeterlinck is noted for his longstanding expertise in corporate governance and M&A work.
Legal 500 Editorial commentary
Key clients
- Eurofins
Work highlights
- Represented the European Commission and the 27 Member States against AstraZeneca for its delays of delivery of millions of doses of Covid-19 vaccines to the EU. After a judicial victory for the EC in summary proceedings, the parties found an amicable settlement.
- Representing Samsung Bioepis against Novartis in a revocation action that was brought before the Brussels Business Court in February 2023. In these proceedings the nullity of the Belgian portion of three European patents owned by Novartis is invoked. The three patents are divisionals of a same European patent that has been revoked earlier in opposition proceedings before the EPO.
- Acting for EG, a producer and distributor of generic medicines, in matters of advertising law related to medicines (market practices and specific regulatory rules).
Practice head
The lawyer(s) leading their teams.
Eric De Gryse, Rafaël Jafferali, Axel Maeterlinck